IFCAH
IFCAH 2026 Call for Projects is now open!
IFCAH (International Fund Congenital Adrenal Hyperplasia) in partnership with ESPE (European Society for Paediatric Endocrinology) and ESE (European Society of Endocrinology) is delighted to announce its 2026 call for projects.
Deadline for a letter of intent application is 15 January 2026. Please make sure you receive a confirmation email after sending IFCAH the letter of intent. If this is not the case, please contact IFCAH at cfp@ifcah.org
Information about IFCAH and this call for projects is available on the IFCAH’s web site or by sending an email to cfp@ifcah.org. Specific forms for letters of intent can be obtained from cfp@ifcah.org
15 January 2026: Letters of intention (LOI) due date
February 2026: LOI decision meeting
April 2026: Full application due date (for accepted LOIs)
June 2026: Audition of proposals
July 2026: Award notification
Background and further information
Background
IFCAH (International Fund Congenital Adrenal Hyperplasia) is a private fundraising organisation aiming to promote academic research on Congenital Adrenal Hyperplasia. Created in 2010 by parents of children affected by CAH (Congenital Adrenal Hyperplasia), IFCAH aims at giving a strong support to research dedicated to improve patients life’s quality.
In 2024, IFCAH launches its call for proposals, in association with ESPE and ESE. A total amount of €350.000 is associated to this program. Participation is open worldwide and will, if possible, include teams based in Europe.
Specific goals
Proposition of new therapeutic targets and protocols
Pharmacotherapy, development of gene or/and cellular therapy models, improvement of current treatment monitoring.
Increasing knowledge on pathophysiology of CAH
The projects should be relevant to CAH. The projects could include research on adrenal development, differentiation and homeostasis, but in any case, relevance to CAH should be emphasized. Research on adrenal tumours and cancer is excluded from this call.
Prevention, diagnostic and treatment of natural or iatrogenic complications
Impact on foetal development, growth, puberty, effects on metabolic and cardiovascular systems, male and female fertility, bone density, immunity, infection, neuro cognition.
Funding
Selected research projects will be supported up to EUR 150k (total). The funding period will have to start at the latest 6 months after notification of the award and will not exceed three years. Funds will have to be used for expenses directly linked to the project, including specific equipment, operating costs or salaries of coworkers (with the exception of salaries of senior permanent staff of academic and governmental agencies which are not eligible). Indirect costs or managements fees are not eligible and must be covered by another source. The funding is open to co-funding opportunities in order to support larger projects.
Eligibility
Applicants must hold an M.D., Ph.D., or equivalent academic degree and have a faculty position or equivalent at a college, university, medical school, or comparable institution. Only one project from a research team will be considered. Applications for the renewal of an IFCAH’s support are accepted but applications for a different project, from a team previously supported by IFCAH, will not be considered, up to the end of its former grant.
Selection procedures
The information given on LOI will enable the scientific board of IFCAH, ESPE and ESE to access the priority of the projects and to determine whether the proposed research merits a full application. Applicants will have to inform on project positioning versus international competitors. Full applications will be requested from selected LOIs and submitted to peer-review. Final selection will take place after an oral project’s presentation (on site in Paris or through video-conference) to the IFCAH, ESPE and ESE board. An email confirming that the IFCAH team has received your application will be addressed to you. Please contact IFCAH at cfp@ifcah.org if you do not receive this confirmation.